

COME HOME Pancreatic Adenocarcinoma Diagnostic/Therapeutic Pathway, v10 May 2015

Required Structured Data Fields:

- ICD9 Code
- Stage
- Performance Status
- Treatment Type (Neoadjuvant, Adjuvant, Etc.)
- Treatment Intent (Curative, Palliative, Maintenance, Etc.)

Diagnostic workup:

Required tests:

Event: Pancreatic protocol CT or MRI

Timing: On or before diagnosis date

Population: Resectable patients

Required: Yes

Data elements: Procedure code or results present in EHR

** Note: will be evaluated by random audit in first release of pathway.

Event: History and Physical

Timing: Within one month of first visit

Population: All patients

Required: Yes

Data elements: Procedure code or results present in EHR

Event: Liver function tests

Timing: Within one week of first visit, within one week of the start of each cycle of chemo.

Population: All patients

Required: Yes

Data elements: Procedure code or results present in EHR

Event: CA 19-9

Timing: Within one month of first visit.

Population: All patients

Required: Yes

Data elements: Procedure code or results present in EHR

**Note: Additional CA 19-9 tests are optional at the discretion of the physician. Only the initial test will be monitored for compliance.

Event: Biopsy of primary tumor and/or metastasis

Timing: Prior to diagnosis

Population: All Patients

Required: Yes

Data elements: Procedure code or results present in EHR

Optional tests:

Chest CT – required for resectable pts / optional for non-resectable

Endoscopic Ultrasonography (EUS)

ERCP and/or MRI/MRCP


Laparoscopy

Quality Measure(s):

Stage entered as structured data within one month of first visit


*Merrimack study may be approved in the next 6-8 months: Phase III, second-line pancreatic cancer study using nab- irinotecan after gemcitabine.

Neoadjuvant Therapy:




*CH PANC 2: McGinn Regimen, see page 8


Adjuvant Therapy:



Locally Advanced:



Metastatic Disease/Recurrence After Resection:



Reaching out to physicians who are using PANC 9 (FOLFOX) in first line to see if they have literature to support this.

CH PANC 1: FOLFIRINOX

Irinotecan (Camptosar) 180 mg/m² IV day 1
 Oxaliplatin (Eloxatin) 85 mg/m² IV day 1
 Leucovorin 400 mg/m² IV day 1
 5-FU 400 mg/m² IV day 1
 5-FU CIVI 2400 mg/m² over 46 hrs

CH PANC 2: GEM + XRT

MCCM Protocol from Annals of Surgical Oncology 2006, see next page

CH PANC 3: 5FU + XRT

5FU 225 mg/m²/day 5-7 days per week
 XRT 5-7 days per week for 5 weeks

CH PANC 4: Capecitabine + XRT

Capecitabine 825 mg/m² BID 5 days/week
 XRT 5-7 days per week for 5 weeks

CH PANC 5: GEM – 5FU/XRT – GEM

Gemcitabine 500-1000 mg/m² IV weekly x 3 weeks
Then (1-2 weeks later):
 5-FU 225 mg/m²/day CIVI during XRT for 42 days
Then:
 Gemcitabine 500-1000 mg/m² IV days 1, 8, 15
 Every 28 days x 3 cycles

CH PANC 6: Gemcitabine

1000 mg/m² days 1, 8, 15, every 28 days

CH PANC 7: 5FU/Leucovorin

Leucovorin 500 mg/m² day 1, 8, 15, 22, 29, 36
 5FU 500 mg/m² day 1, 8, 15, 22, 29, 36

CH PANC 8: Gemcitabine + nab-Paclitaxel

Gemcitabine 1000 mg/m²/day day 1, 8, 15
 nab-Paclitaxel 125 mg/m² day 1, 8, 15
 Cycled every 28 days

CH PANC 9: FOLFOX

Oxaliplatin 85 mg/m² IV day 1
 Leucovorin 400 mg/m² IV day 1
 5-FU 400 mg/m² IV day 1
 5-FU CIVI 2400 mg/m² over 46 hrs

CH PANC 10: CapeOX

Oxaliplatin 130 mg/m² IV day 1
 Capecitabine 1000 mg/m² BID oral days 1-14
 Cycled every 21 days

CH PANC 11: GEM – Cape/XRT – GEM

Gemcitabine 500-1000 mg/m² IV weekly x 3 weeks
Then (1-2 weeks later):
 Capecitabine 825 mg/m² BID during XRT for 42 days
Then:
 Gemcitabine 500-1000 mg/m² IV days 1, 8, 15
 Every 28 days x 3 cycles

CH PANC 2: Gem + XRT




FIG. 1. Treatment schema of full-dose gemcitabine (1000 mg/m²) and concurrent radiation (36 Gy in 2.4-Gy fractions). Gemcitabine was administered on days 1 and 8 of a 21-day cycle before and after a 28-day cycle of gemcitabine on days 1, 8, and 15 and concurrent radiation on days 1 to 19. XRT, radiotherapy.

Ann Surg Oncol. 2006 Feb;13(2):150-8. Epub 2006 Jan 19. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma.